Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Bartz R, Fukuchi K, Ohtsuka T, Lange T, Gruner K, Watanabe I, Hayashi S, Oda Y, Kawaida R, Komori H, Kashimoto Y, Wirtz P, Mayer JA, Redondo-Müller M, Saito S, Takahashi M, Hanzawa H, Imai E, Martinez A, Hanai M, Häussinger D, Chapman RW, Agatsuma T, Bange J, Abraham R. Bartz R, et al. Among authors: agatsuma t. Mol Cancer Ther. 2019 Oct;18(10):1832-1843. doi: 10.1158/1535-7163.MCT-18-0048. Epub 2019 Jul 26. Mol Cancer Ther. 2019. PMID: 31350344
Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals.
Fukuchi K, Nanai K, Yuita H, Maru C, Tsukada J, Ishigami M, Nagai Y, Nakano Y, Yoshimura C, Yoneda K, Amano M, Nakamura K, Oda Y, Nishigohri H, Yamamoto S, Ohnishi-Totoki Y, Inaki K, Komori H, Nakano R, Kanari Y, Nishida A, Matsui Y, Funo S, Takahashi S, Ohtsuka T, Agatsuma T. Fukuchi K, et al. Among authors: agatsuma t. J Oncol. 2022 Nov 4;2022:3552793. doi: 10.1155/2022/3552793. eCollection 2022. J Oncol. 2022. PMID: 36385956 Free PMC article.
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates.
Sue M, Tsubaki T, Ishimoto Y, Hayashi S, Ishida S, Otsuka T, Isumi Y, Kawase Y, Yamaguchi J, Nakada T, Ishiguro J, Nakamura K, Kawaida R, Ohtsuka T, Wada T, Agatsuma T, Kawasaki N. Sue M, et al. Among authors: agatsuma t. PLoS One. 2024 Jun 6;19(6):e0304985. doi: 10.1371/journal.pone.0304985. eCollection 2024. PLoS One. 2024. PMID: 38843278 Free PMC article.
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.
Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, Kitamura M, Wada T, Agatsuma T. Hasegawa J, et al. Among authors: agatsuma t. Cancer Biol Ther. 2016 Nov;17(11):1158-1167. doi: 10.1080/15384047.2016.1235663. Epub 2016 Sep 21. Cancer Biol Ther. 2016. PMID: 27653549 Free PMC article.
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, Fujitani T, Honda T, Shibutani T, Muramatsu S, Nakada T, Goto R, Takahashi S, Yamaguchi M, Hamada H, Noguchi Y, Murakami M, Abe Y, Agatsuma T. Okajima D, et al. Among authors: agatsuma t. Mol Cancer Ther. 2021 Dec;20(12):2329-2340. doi: 10.1158/1535-7163.MCT-21-0206. Epub 2021 Aug 19. Mol Cancer Ther. 2021. PMID: 34413126 Free PMC article.
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A, Nishiya Y, Shibutani T, Aida T, Hayakawa I, Nakada T, Abe Y, Agatsuma T. Yamato M, et al. Among authors: agatsuma t. Mol Cancer Ther. 2022 Apr 1;21(4):635-646. doi: 10.1158/1535-7163.MCT-21-0554. Mol Cancer Ther. 2022. PMID: 35149548 Free PMC article.
242 results